Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPS1 | P31327 | 2/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2170598 | 0.91 | CES2 (0.36) | CES2CES1KMT2AEPHX2 | |
| SCHEMBL3239807 | 0.90 | MEN1 (0.32) | KMT2AEPHX2 | |
| SCHEMBL2169753 | 0.89 | P2RX7 (0.42) | KDM4EKMT2A | |
| SCHEMBL2170049 | 0.88 | HCRTR1 (0.40) | KMT2AEPHX2 | |
| SCHEMBL2170340 | 0.87 | HCRTR1 (0.42) | KMT2A | |
| SCHEMBL2169787 | 0.87 | HCRTR1 (0.38) | KMT2A | |
| SCHEMBL2169957 | 0.86 | EPHX2 (0.39) | KDM4EHTTKMT2AEPHX2 | |
| SCHEMBL2170275 | 0.83 | ALDH1A1 (0.40) | SMN1; SMN2KMT2AEPHX2 | |
| SCHEMBL2170533 | 0.83 | CXCR3 (0.38) | KDM4EKMT2AEPHX2 | |
| SCHEMBL2170172 | 0.82 | HPGD (0.41) | CES2CES1SMN1; SMN2HTTEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252781-B2 | 1,2-diazetidin-3-one derivatives and drugs containing same | KOWA COMPANY, LTD. (JP) | 2012-08-28 | — | — | US | disclosed |
| US-8252781-B2 | 1,2-diazetidin-3-one derivatives and drugs containing same | KOWA COMPANY, LTD. (JP) | 2012-08-28 | — | — | US | disclosed |
| US-8252781-B2 | 1,2-diazetidin-3-one derivatives and drugs containing same | KOWA COMPANY, LTD. (JP) | 2012-08-28 | — | — | US | disclosed |
| EP-2348019-A1 | 1,2-DIAZETIDIN-3-ONE DERIVATIVE AND PHARMACEUTICAL AGENT COMPRISING SAME | Kowa Company, Ltd. (JP) | 2011-07-27 | — | — | EP | disclosed |
| EP-2348019-A1 | 1,2-DIAZETIDIN-3-ONE DERIVATIVE AND PHARMACEUTICAL AGENT COMPRISING SAME | Kowa Company, Ltd. (JP) | 2011-07-27 | — | — | EP | disclosed |
| US-20100144694-A1 | 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME | KOWA COMPANY, LTD. (JP) | 2010-06-10 | — | — | US | disclosed |
| US-20100144694-A1 | 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME | KOWA COMPANY, LTD. (JP) | 2010-06-10 | — | — | US | disclosed |
| US-20100144694-A1 | 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME | KOWA COMPANY, LTD. (JP) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144694-A1 | 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME | HSD11B1, HSD11B2, HSD3B1 | CPS1 1492/4885CES2 433/4885CES1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.